JP2005529904A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529904A5
JP2005529904A5 JP2004500865A JP2004500865A JP2005529904A5 JP 2005529904 A5 JP2005529904 A5 JP 2005529904A5 JP 2004500865 A JP2004500865 A JP 2004500865A JP 2004500865 A JP2004500865 A JP 2004500865A JP 2005529904 A5 JP2005529904 A5 JP 2005529904A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ethylphenyl
triazole
methoxyphenyl
uveitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004500865A
Other languages
English (en)
Other versions
JP2005529904A (ja
Filing date
Publication date
Priority claimed from US10/137,699 external-priority patent/US6797722B2/en
Application filed filed Critical
Publication of JP2005529904A publication Critical patent/JP2005529904A/ja
Publication of JP2005529904A5 publication Critical patent/JP2005529904A5/ja
Pending legal-status Critical Current

Links

Claims (4)

  1. (3−(2−エチルフェニル)−5−メトキシフェニル)−1H−[1,2,4]−トリアゾールを含む、多発性硬化症、全身性エリテマトーデス、関節リウマチおよびブドウ膜炎からなる群から選択される自己免疫疾患の治療のための医薬組成物。
  2. (3−(2−エチルフェニル)−5−メトキシフェニル)−1H−[1,2,4]−トリアゾールを含む、γδT細胞の阻害のための医薬組成物。
  3. 乳類のためのものである、請求項1または2のいずれかの医薬組成物。
  4. 該哺乳類がヒトである請求項医薬組成物。

JP2004500865A 2002-05-03 2003-04-15 自己免疫疾患の治療のための(3−(2−エチルフェニル)−5−メトキシフェニル)−1h−[1,2,4]−トリアゾールの使用 Pending JP2005529904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
PCT/IT2003/000237 WO2003092681A1 (en) 2002-05-03 2003-04-15 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2005529904A JP2005529904A (ja) 2005-10-06
JP2005529904A5 true JP2005529904A5 (ja) 2006-06-08

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500865A Pending JP2005529904A (ja) 2002-05-03 2003-04-15 自己免疫疾患の治療のための(3−(2−エチルフェニル)−5−メトキシフェニル)−1h−[1,2,4]−トリアゾールの使用

Country Status (15)

Country Link
US (2) US6797722B2 (ja)
EP (1) EP1501505B1 (ja)
JP (1) JP2005529904A (ja)
KR (1) KR20040111491A (ja)
AT (1) ATE315935T1 (ja)
AU (1) AU2003224453A1 (ja)
CA (1) CA2483904A1 (ja)
DE (1) DE60303296T2 (ja)
DK (1) DK1501505T3 (ja)
ES (1) ES2257666T3 (ja)
MX (1) MXPA04010785A (ja)
PL (1) PL374252A1 (ja)
PT (1) PT1501505E (ja)
TW (1) TWI284532B (ja)
WO (1) WO2003092681A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
DK1002792T3 (da) * 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (en) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
JP2004532847A5 (ja)
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
NO20053773D0 (no) Parentale peptidformuleringer for behandling av systemisk lupus erytematosus
NO20070973L (no) Antagonisering av interleukin-21 reseptoraktivitet
CA2289851A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
JP2004538039A5 (ja)
EP1177794A3 (en) Composition, containing lactobacillus bulgaricus and streptococcus thermophilus, for the treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases, and obesity
IS2110B (is) Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar
DE60016631D1 (de) Ester abgeleitet vom (rr,ss)-2-hydroxybenzoat des 3-(2-dimethylaminomethyl-1-hydroxycyclohexl)phenyl
JP2001194792A5 (ja)
JP2001512767A5 (ja)
JP2007511047A5 (ja)
DE69913471D1 (de) Siliconzusammensetzung zur Herstellung vernetzter Trennbeschichtungen
DE69934360D1 (de) Verfahren zur Herstellung von gegen elektrostatische Entladung geschützten Bauelementen mit selbstausgerichteter Silicidstruktur
JP2005529904A5 (ja)
NO20071399L (no) VLA-4-antagonister
WO2007140011A3 (en) Erythroid progenitor cells and methods for producing parvovirus b19 therein
JP2004315516A5 (ja)
FR2831732B1 (fr) Fourniture d'images numeriques geolocalisees personnalisees
JP2007523200A5 (ja)
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
JP2005005118A5 (ja)
AU2002337037A1 (en) Compositions and methods for detecting multidrug resistant strains of m. tuberculosis having mutations in genes of the mutt family
AU3849699A (en) Hydroxamic acid derivatives and medicinal utilization thereof
JP2004526429A5 (ja)